RBC Capital Sticks to Its Buy Rating for Cytokinetics (CYTK)

In a report released today, Leonid Timashev from RBC Capital maintained a Buy rating on Cytokinetics, with a price target of $101.00.

President's Day Sale - 70% Off

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Timashev covers the Healthcare sector, focusing on stocks such as Exelixis, Cytokinetics, and BeOne Medicines. According to TipRanks, Timashev has an average return of 19.0% and a 56.44% success rate on recommended stocks.

In a report released yesterday, Barclays also maintained a Buy rating on the stock with a $87.00 price target.

Based on Cytokinetics’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $1.94 million and a GAAP net loss of $306.18 million. In comparison, last year the company earned a revenue of $463 thousand and had a GAAP net loss of $160.55 million

Based on the recent corporate insider activity of 155 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CYTK in relation to earlier this year. Earlier this month, Andrew Callos, the EVP & CCO of CYTK sold 15,000.00 shares for a total of $928,950.00.